LTI-03

Austin, Texas, August 20, 2026 Rein Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...

Austin, Texas, USA | July 21, 2026 Rein Therapeutics announced that its Phase 2 RENEW clinical trial evaluating the...

AUSTIN, Texas, June 11, 2026 Rein Therapeutics, Inc. (NASDAQ: RNTX) announced the expansion of its ongoing Phase 2 RENEW...